Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status (FLMRD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04934930|
Recruitment Status : Recruiting
First Posted : June 22, 2021
Last Update Posted : June 22, 2021
Follicular lymphoma (FL) is a chronic indolent malignancy, where treatment with 6 cycles of bendamustine obinutuzumab (BO) is highly effective but at a cost of increased adverse events.
Tumor specific DNA can be traced in blood and bone marrow of follicular lymphoma patients even after therapy, and when detected after lymphoma treatment it is referred to as minimal residual disease (MRD).
MRD elimination after effective lymphoma treatment is a marker for deep response and correlates with prolonged remission.
In this study we aim to omit chemotherapy after 4 cycles of treatment in patients achieving MRD elimination after 3 months of therapy, as well as complete metabolic response on positron emission computed tomography (PET-CT), hoping to preserve treatment effectiveness while reducing adverse events.
|Condition or disease||Intervention/treatment||Phase|
|Follicular Lymphoma||Drug: Bendamustin Drug: Obinutuzumab||Phase 2|
Follicular lymphoma (FL) is the second most common type of non-Hodgkin's lymphoma, with an estimated incidence of 3.18 cases per 100000 people a year in the United States The disease is characterized by an indolent behavior, where often treatment is unnecessary at diagnosis, and a "watch & wait" approach is the standard of care for asymptomatic patients. FL is also a highly responsive disease for immuno-chemotherapeutic combinations, although most patients will eventually relapse. Since the disease is incurable & indolent in nature, the therapeutic strategy should aim for disease control, while using treatments with high safety profile in order to minimize the chance for life threatening adverse events.
Therapy with rituximab cyclophosphamide, doxorubicin, vincristine & prednisone (R-CHOP) combination & subsequent rituximab maintenance therapy for 24 months shows excellent results with a median progression free survival (PFS) of above a decade.
The more recent GALLIUM trial has shown that combining the monoclonal antibody obinutuzumab with chemotherapy is even more efficacious compared to rituximab combinations. When different combinations were examined in this trial the best results were achieved with the bendamustine-obinutuzumab (BO) combination with 3 year PFS of 84%. Unfortunately the trial also revealed a downside for this effective combination with higher rate of fatal adverse events among patients receiving 6 cycles of bendamustine combinations.
In patients with acute leukemia evaluation for minimal residual disease (MRD) is a routine procedure, and the nature & length of treatment are guided by MRD status at different time points during therapy.
Among FL patients treated with obinutuzumab-chemotherapy combinations, it has been shown that after 3 cycles of treatment about 90% of patients were MRD negative. In addition MRD negativity at the end of induction in either peripheral blood or bone marrow was found to be associated with improved outcomes in patients with 1st line treatment for FL as well as in the relapsed setting.
These findings raise the possibility for an MRD based treatment approach, where the duration of chemotherapy could be guided by MRD status at mid-induction. Eliminating chemotherapy while continuing immunotherapy after achievement of MRD negativity & complete metabolic remission on PET-CT at mid-induction could reduce treatment toxicity, while potentially preserving efficacy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Prospective multicenter, single arm, phase II study|
|Masking:||None (Open Label)|
|Official Title:||Adjustment of Chemotherapy Duration in Follicular Lymphoma Patients According to Peripheral Blood or Bone Marrow Minimal Residual Disease Status|
|Actual Study Start Date :||January 29, 2020|
|Estimated Primary Completion Date :||August 1, 2025|
|Estimated Study Completion Date :||August 1, 2025|
Experimental: Reduced number of bendamustine cycles in patients with mid-induction MRD negativity
Patients with follicular lymphoma treated with obinutuzumab bendamustine & achieving MRD negativity as well as complete metabolic response on PET-CT at mid-induction would continue obinutuzumab treatment while omitting bendamustin after 4 cycles.
Other Name: Ribomustin
Other Name: Gazyva
- Progression free survival among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab. [ Time Frame: Progression free survival will be assessed 24 months after the end of induction. ]Progression-free survival is defined as the time from randomization to the earliest event of progression, relapse, or death from any cause. progression-free survival, is assessed by the investigator.
- Progression of disease within 24 months (POD24) [ Time Frame: POD24 will be assessed at 24 months after treatment initiation ]POD24 is defined as disease progression or death due to disease progression occurring within 24 months after treatment initiation, as assessed by the investigator.
- Overall survival among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab. [ Time Frame: Overall survival will be assessed 24 months after the end of induction. ]Overall survival is defined as the time from study initiation to death from any cause.
- The rate of MRD negativity persistence at 12 months among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab. [ Time Frame: Persistence of MRD negativity will be assessed 12 months after study initiation. ]MRD will be assessed at mid-induction, end of induction and subsequently every 6 months.
- The proportion of adverse events among patients treated with 4 cycles of BO & 2 additional cycles of obinutuzumab. [ Time Frame: The proportion of various adverse events will be assessed until 24 months from the end of induction. ]The proportion of various adverse events will be assessed as documented by the investigator.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04934930
|Contact: Uri Abadi, MDfirstname.lastname@example.org|
|Meir medical center||Recruiting|
|Kfar Saba, Israel|
|Contact: Uri Abadi, MD 972-9-7472786 email@example.com|
|Principal Investigator:||Uri Abadi, MD||Meir Medical Center|